AARTIPHARM — Aarti Pharmalabs Balance Sheet
0.000.00%
- IN₹80.27bn
- IN₹83.87bn
- IN₹21.15bn
- 88
- 19
- 85
- 73
Annual balance sheet for Aarti Pharmalabs, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Interim Report | Interim Report | ARS | ARS | PRESS |
Standards: | — | — | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 2.5 | 1,603 | 990 | 1,007 | 613 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0 | 3,882 | 4,524 | 5,893 | 6,732 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 2.5 | 10,281 | 11,558 | 13,456 | 13,222 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0 | 9,453 | 9,861 | 10,932 | 14,107 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 2.5 | 20,399 | 22,309 | 25,821 | 29,064 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.219 | 5,807 | 5,916 | 6,944 | 6,570 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 0.219 | 6,534 | 6,724 | 8,251 | 9,165 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 2.28 | 13,865 | 15,585 | 17,570 | 19,899 |
Total Liabilities & Shareholders' Equity | 2.5 | 20,399 | 22,309 | 25,821 | 29,064 |
Total Common Shares Outstanding |